Brickell Biotech Stock

Brickell Biotech EBIT per Share

Delisted

The EBIT per Share of Brickell Biotech (BBI) as of Aug 5, 2026 is -7.67 USD.

EBIT per Share

-7.67USD

Last updated:

EBIT per Share of Brickell Biotech is 2026 -7.67 USD. EBIT per Share of Brickell Biotech was 2025 0.00 USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

Brickell Biotech Stock analysis

What does Brickell Biotech do? Brickell Biotech Inc is a biopharmaceutical company that focuses on the development and marketing of innovative dermatology products. The company was founded in 2009 and is headquartered in Boulder, Colorado (USA), with branches in California and Singapore. The history of Brickell Biotech dates back to the 1960s when the company was originally founded under the name Brickell Research Inc. Over the following decades, the company specialized in biological research and conducted important research that forms the basis for today's product development. Brickell Biotech's business model is based on the creation of new and innovative therapies for the treatment of various dermatological diseases. In recent years, the company has entered into a number of important partnerships to accelerate its product development and strengthen its position in the industry. Brickell Biotech operates in two main areas: pharmaceuticals and cosmetic products. In the pharmaceuticals area, the company has a number of promising therapies in the pipeline that target the treatment of skin cancer, psoriasis, and other dermatological conditions. The company's flagship product is Sofpironium Bromide, a potential treatment for hyperhidrosis (excessive sweating). In the cosmetic products area, the company has developed a range of skincare products tailored to the needs of people with sensitive, dry, or aging skin. These products include moisturizers, cleansers, and anti-aging products, all made from high-quality ingredients. Brickell Biotech works closely with the scientific community to explore the latest developments and innovations in dermatology and the cosmetics industry. The company has also established a strong presence in the medical and research sectors by collaborating closely with leading universities and medical institutions worldwide. Overall, Brickell Biotech is a promising company in the biopharmaceutical and cosmetics industry, specializing in the development of new and innovative therapies for the treatment of skin conditions. With a strong pipeline of products and a dedicated leadership team, the company is expected to continue growing and establish itself as an important player in the industry. Brickell Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Brickell Biotech stock

EBIT per Share of Brickell Biotech is -7.67 USD in 2026.

On Eulerpool you can find the complete historical development of EBIT per Share Brickell Biotech since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

Income Statement — Brickell Biotech

All Key Metrics — Brickell Biotech